« 5 Tips for Children with ADHD | Main | Nuerofeedback Therapy and Brain Imaging Diagnosis »
March 22, 2006
Pediatric Board Does Not Recommend ADHD Drug Re-Labeling
The Food and Drug Administration pediactric advisory committee recommended that Ritalin and other like drugs for attention deficit hyperactivity disorder should not carry strong "black-box" warnings. These labels would have warned about cardiovascular and psychiactic risks. The advisory panel did recommend that labels be worded so that people can actually understand it.
A month earlier another panel advising the FDA recommended they push for a warning labels based on a 2004 FDA report that says 25 people died taking ADHD drugs and 43 people experienced strokes, cardiac arrest and heart palpitations between 1999 and 2003.
However todays recommendation may be followed by the FDA.
Food and Drug Administration: http://www.fda.gov
Posted by ernestpr at March 22, 2006 05:37 PM
Comments
Post a comment
Thanks for signing in, . Now you can comment. (sign out)
(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)